<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573974</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO14-TL/METERMUCADIG</org_study_id>
    <secondary_id>2015-A00683-46</secondary_id>
    <secondary_id>2015-R25</secondary_id>
    <secondary_id>150963B-12</secondary_id>
    <nct_id>NCT02573974</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer</brief_title>
  <acronym>METERMUCADIG</acronym>
  <official_title>Study of Alterations in Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inserm U1069 - Team Nutrition, Growth and Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Undernutrition associated with cancer, or cancer cachexia results from a deterioration of the
      energy balance that leads to a gradual mobilization of energy reserves in the body and to
      increasing deterioration of the nutritional status of patients. This will thus significantly
      reduce quality of life and survival of patients with a lower tolerance to cancer treatments.
      Despite undeniable progress in knowledge, many pathophysiological mechanisms remain few or
      not explored, which could explain that there is still no satisfactory therapeutic solution to
      halt the gradual deterioration of the nutritional status of patients. In this sense, apart
      from preclinical data obtained in animal models, there is currently no clinical study on the
      functioning of skeletal muscle energy metabolism in undernourished patients suffering of
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2016</start_date>
  <completion_date type="Actual">December 4, 2018</completion_date>
  <primary_completion_date type="Actual">December 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of muscle mitochondrial bioenergetics</measure>
    <time_frame>An average of one week</time_frame>
    <description>Measurement of muscle mitochondrial bioenergetics by high resolution oxygraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of muscle lipid droplets</measure>
    <time_frame>An average of one week</time_frame>
    <description>Quantification of muscle lipid droplets by electron microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the expression of target genes and proteins</measure>
    <time_frame>An average of one week</time_frame>
    <description>Analysis of the expression of target genes and proteins involved in 1/ mitochondrial metabolism 2/ lipid metabolism 3/ the regulation of energy metabolism and 4/ muscle proteolysis by RTqPCR with SYBR Green and by Western Blot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of body composition (fat mass / lean mass)</measure>
    <time_frame>Within 4 weeks before inclusion</time_frame>
    <description>Determination of body composition ( fat mass / lean mass ) by an imaging method scannographic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining the isotopic composition of nitrogen hair</measure>
    <time_frame>An average of one week</time_frame>
    <description>Determining the isotopic composition of nitrogen hair spectrometry .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Undernutrition</condition>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the intervention, specific to the study, is to take samples on patients with advanced gastrointestinal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the intervention, specific to the study, is to take samples on non-undernourished patients supported for adjuvant chemotherapy as part of colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples</intervention_name>
    <description>Blood samples, muscle biopsy and sample of hair</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Case group selection criteria:

        Inclusion Criteria:

          -  18 years ≤ Age ≤ 80 years

          -  Colorectal pancreatic cancer

          -  Undernutrition related to cancer (weight loss &gt; 5% weight in one month or 10% in 6
             months)

          -  Indication to systemic chemotherapy

          -  Indication to the development of an implantable port

          -  Life expectancy ≥ 3 months

          -  WHO General Status ≤ 2

          -  Patients affiliated to social security scheme

          -  Informed consent signed by the patient

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Unbalanced Diabetes

          -  Systemic corticosteroid treatment

          -  Any severe uncontrolled medical condition

          -  Alopecia

        Control group selection criteria:

        Inclusion Criteria:

          -  18 years ≤ Age ≤ 80 years

          -  Colorectal pancreatic cancer

          -  Indication adjuvant chemotherapy

          -  Indication to the development of an implantable port

          -  Life expectancy ≥ 3 months

          -  WHO General Status ≤ 2

          -  Patients affiliated to social security scheme

          -  Informed consent signed by the patient

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Undernutrition related cancer (weight loss &gt; 5% weight in one month or 10% in 6
             months)

          -  Unbalanced Diabetes

          -  Systemic corticosteroid treatment

          -  Any severe uncontrolled medical condition

          -  Alopecia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry LECOMTE, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hépato-gastroentérologie et de Cancérologie Digestive, CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>undernutrition</keyword>
  <keyword>gastrointestinal cancer</keyword>
  <keyword>skeletal muscle</keyword>
  <keyword>energy metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

